Cytokine secretion in long-standing diabetes mellitus type 1 and 2: Associations with low-grade systemic inflammation

被引:109
作者
Alexandraki, Krystallenia I. [2 ,3 ]
Piperi, Christina [2 ]
Ziakas, Panayiotis D. [3 ]
Apostolopoulos, Nikolaos V. [4 ]
Makrilakis, Konstantinos [5 ]
Syriou, Vassiliki [3 ]
Diamanti-Kandarakis, Evanthia [6 ]
Kaltsas, Gregory [3 ]
Kalofoutis, Anastasios [1 ,2 ]
机构
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Biol Chem Lab, Athens 11528, Greece
[3] Natl & Kapodistrian Univ Athens, Sch Med, Laiko Univ Hosp, Dept Pathophysiol,Div Endocrinol, Athens 11528, Greece
[4] Homerton Univ Hosp, Dept Obstet & Gynecol, London, England
[5] Natl & Kapodistrian Univ Athens, Sch Med, Laiko Univ Hosp, Diabetol Ctr,Dept Propedeut Med 1, Athens 11528, Greece
[6] Natl & Kapodistrian Univ Athens, Sch Med, Dept Med 1, Div Endocrinol, Athens 11528, Greece
关键词
cytokines; C-reactive protein; interleukin-1; beta; interleukin-6; tumor necrosis factor-alpha; diabetes mellitus type 1; diabetes mellitus type 2; peripheral blood mononuclear cells; ELISPOT;
D O I
10.1007/s10875-007-9164-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Low-grade systemic chronic inflammation is a very well-known feature of diabetes mellitus (DM). The purpose of this study was the assessment of the proinflammatory cytokine secretion profile in long-standing diabetes along with the presence of features of systemic inflammation. Metabolic parameters and serum high-sensitivity C-reactive protein, interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha levels were determined in 20 patients with type 1 DM and 21 patients with type 2 DM and compared to 34 healthy subjects. The number of cytokine-secreting peripheral blood mononuclear cells (PBMCs), before and after mitogenic stimulation, was also determined in the same groups. Adverse lipid profile, higher levels of inflammatory markers, and higher count of cytokine-secreting cells were observed more prevalently in type 2 diabetics than in controls. After stimulation, the increase in number of cytokine-secreting cells was higher in controls. In conclusion, patients with DM have evidence of low-grade inflammation and abnormal PBMC function that could be related to long-term sequelae, the accelerated atherosclerotic process, and the susceptibility to infections.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 56 条
[1]   Fatty acids potentiate interleukin-1β toxicity in the β-cell line INS-1E [J].
Aarnes, M ;
Schonberg, S ;
Grill, V .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (01) :189-193
[2]   INTERLEUKIN-6 IN BIOLOGY AND MEDICINE [J].
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 :1-78
[3]  
American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5
[4]   Human chemokines: An update [J].
Baggiolini, M ;
Dewald, B ;
Moser, B .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :675-705
[5]  
Buzzetti R, 1998, DIABETES METAB REV, V14, P111, DOI 10.1002/(SICI)1099-0895(199806)14:2<111::AID-DMR211>3.3.CO
[6]  
2-U
[7]   Neutrophil-derived proteins: Selling cytokines by the pound [J].
Cassatella, MA .
ADVANCES IN IMMUNOLOGY, VOL 73, 1999, 73 :369-509
[8]   Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development [J].
Celi, F. ;
Bini, V. ;
Papi, F. ;
Santilli, E. ;
Castellani, M. S. ;
Ferretti, A. ;
Mencacci, M. ;
Berioli, M. G. ;
De Giorgi, G. ;
Falorni, A. .
DIABETIC MEDICINE, 2006, 23 (06) :660-665
[9]   IN-VITRO SECRETION OF INTERLEUKIN-1-BETA AND INTERFERON-GAMMA BY PERIPHERAL-BLOOD LYMPHOMONONUCLEAR CELLS IN DIABETIC-PATIENTS [J].
CIAMPOLILLO, A ;
GUASTAMACCHIA, E ;
CARAGIULO, L ;
LOLLINO, G ;
DEROBERTIS, O ;
LATTANZI, V ;
GIORGINO, R .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1993, 21 (2-3) :87-93
[10]   Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-α production in NIDDM patients after gliclazide treatment [J].
Desfaits, AC ;
Serri, O ;
Renier, G .
DIABETES CARE, 1998, 21 (04) :487-493